Ascendis Pharma A (ASND) Non Operating Interest Expenses (2013 - 2018)

Ascendis Pharma A (ASND) has 6 years of Non Operating Interest Expenses data on file, last reported at -$436013.4 in Q4 2018.

• For the quarter ending Q4 2018, Non Operating Interest Expenses fell 21.81% year-over-year to -$436013.4; the trailing twelve-month figure through Dec 2018 stood at -$1.3 million (down 6.48% YoY), and the FY2018 full-year result was -$451268.2, down 31.44% from the prior year.
• Non Operating Interest Expenses eased to -$436013.4 in Q4 2018, from -$357939.5 in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of -$250496.0 in Q4 2016 to a low of -$436013.4 in Q4 2018.
• A 5-year average of -$337536.1 and a median of -$354952.7 in 2014 frame the typical range for Non Operating Interest Expenses.
• Across the five-year window, Non Operating Interest Expenses plunged 586.28% in 2014 and advanced 18.78% in 2015, its largest moves.
• Tracing ASND's Non Operating Interest Expenses over 5 years: stood at -$354952.7 in 2014, then increased by 18.78% to -$288278.8 in 2015, then advanced by 13.11% to -$250496.0 in 2016, then tumbled by 42.89% to -$357939.5 in 2017, then retreated by 21.81% to -$436013.4 in 2018.
• Business Quant data shows ASND's Non Operating Interest Expenses at -$436013.4 in Q4 2018, -$357939.5 in Q4 2017, and -$250496.0 in Q4 2016.